Navigation Links
Cooling decreases heart attack effects

Reducing body temperature by just a few degrees minimises brain damage resulting from a cardiac arrest.When the heart suddenly stops - cardiac arrest - there's a great danger that the brain will be starved of oxygen. //Even if the person survives, they run the risk of permanent brain damage. It's been suggested that perhaps cooling the body can reduce the brain's demand for oxygen and this may protect it after a cardiac arrest.

Doctors in Vienna have been testing this idea. They looked at patients who had experienced cardiac arrest due to ventricular fibrillation - an abnormal heart rhythm. One group had their body temperature reduced to 34 to 32 degrees - hypothermia - over 24 hours, while the other group received normal care.

After six months, 50 per cent of the hypothermia group had had a good neurologic outcome, with minimal disability, compared to 20 per cent of controls. Mortality at six months was 30 per cent in the hypothermia group, compared to 10 per cent in the controls. But there was no difference between the two groups in the complication rate seven days following the arrest. The study shows that hypothermia may indeed be an effective treatment for cardiac arrest.


'"/>




Page: 1

Related medicine news :

1. Cooling treatment for newborn asphyxia
2. Stroke Patients May Benefit By Wearing Cooling Helmets
3. Cooling Can Reduce The Risk Of Brain Damage In Oxygen Deprived Newborns
4. Effect Of Cooling And Exercise To Be Analyzed In Patients With Multiple Sclerosis
5. Cooling Off As A Treatment Option For Heart And Trauma Patients
6. Survival After Cardiac Arrest Is Aided By Cooling
7. Current Cooling Devices Ineffective in Preventing Brain Injury
8. Existing Brain Cooling Not Beneficial To Trauma Patients
9. Cooling Towers may Cause Severe Respiratory Diseases
10. Cooling Temperatures Help Crucian Carp
11. Headache decreases appetite
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate ... year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 children ... those children. James saw firsthand the effect of the critical funding gap for research ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) ... a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background in ... “It is with considerable pleasure to welcome back Dr. Kim to the CDG team” ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... From a ... are released almost daily linking gut health to chronic disease, mental health and general ... Year ” as an important resolution to consider. , For one Charlottesville restaurant, good ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 The Philadelphia Pediatric Medical ... developing medical devices for children. The Consortium chose ... seed grants of $50,000 each. The devices under ... nerve signals, a hand-operated rapid blood delivery system for emergency ... babies. ...
(Date:1/18/2017)...   Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to restore ... the Company,s operating results for 2016 and an outline ... Company described in its recent 10-K filing with the ... The Company,s contract laboratory completed its evaluation of NovaDerm®, ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: